These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 38030290)

  • 1. Sacubitril/Valsartan Cannot Improve Cardiac Function Compared with Valsartan in Patients Suffering Nonvalvular Atrial Fibrillation without Systolic Heart Failure.
    Zhu M; Guo J; Qiqike B; Nay X; Dan S; Kuransi A; Hu G; Han Z; Hou D; Aili A; Xia B; Chen P; Bate B; Xie J
    Int Heart J; 2023; 64(6):1032-1039. PubMed ID: 38030290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of sacubitril/valsartan on cardiac function in heart failure rabbits with preserved ejection fraction].
    Gao SY; Yao DH; Li JF; Xie QM; Jiang SC
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):887-893. PubMed ID: 31744278
    [No Abstract]   [Full Text] [Related]  

  • 3. The impact of sacubitril/valsartan on outcome in patients suffering from heart failure with a concomitant diabetes mellitus.
    El-Battrawy I; Demmer J; Abumayyaleh M; Crack C; Pilsinger C; Zhou X; Mügge A; Akin I; Aweimer A
    ESC Heart Fail; 2023 Apr; 10(2):943-954. PubMed ID: 36479630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients.
    Yang L; Zhang M; Hao Z; Wang N; Zhang M
    ESC Heart Fail; 2022 Aug; 9(4):2428-2434. PubMed ID: 35437929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
    Pascual-Figal D; Wachter R; Senni M; Bao W; Noè A; Schwende H; Butylin D; Prescott MF;
    JACC Heart Fail; 2020 Oct; 8(10):822-833. PubMed ID: 32800508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status.
    Murphy SP; Ward JH; Piña IL; Felker GM; Butler J; Maisel AS; Meng X; Prescott MF; Solomon SD; Januzzi JL
    JACC Heart Fail; 2022 Dec; 10(12):976-988. PubMed ID: 36456072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
    Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
    J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study on the Efficacy of Sacubitril/Valsartan in Patients with Heart Failure with Preserved Ejection Fraction Undergoing Peritoneal Dialysis.
    Sheng Y; Ma X; Liu Y; Yang X; Sun F
    Cardiology; 2023; 148(5):385-394. PubMed ID: 37253340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
    Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D
    Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.
    Januzzi JL; Prescott MF; Butler J; Felker GM; Maisel AS; McCague K; Camacho A; Piña IL; Rocha RA; Shah AM; Williamson KM; Solomon SD;
    JAMA; 2019 Sep; 322(11):1085-1095. PubMed ID: 31475295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry.
    Mandoli GE; Pastore MC; Giannoni A; Benfari G; Dini FL; Rosa G; Pugliese NR; Taddei C; Correale M; Brunetti ND; Mazzeo P; Carluccio E; Mengoni A; Guaricci AI; Piscitelli L; Citro R; Ciccarelli M; Novo G; Corrado E; Pasquini A; Loria V; De Carli G; Degiovanni A; Patti G; Santoro C; Moderato L; Cicoira M; Canepa M; Malagoli A; Emdin M; Cameli M
    ESC Heart Fail; 2023 Apr; 10(2):846-857. PubMed ID: 36448244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
    Khan MS; Felker GM; Piña IL; Camacho A; Bapat D; Ibrahim NE; Maisel AS; Prescott MF; Ward JH; Solomon SD; Januzzi JL; Butler J
    JACC Heart Fail; 2021 Feb; 9(2):137-145. PubMed ID: 33309581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction.
    Murphy SP; Prescott MF; Maisel AS; Butler J; Piña IL; Felker GM; Ward JH; Williamson KM; Camacho A; Kandanelly RR; Solomon SD; Januzzi JL
    Circ Heart Fail; 2021 Jun; 14(6):e008410. PubMed ID: 33998243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.
    Shah AM; Claggett B; Prasad N; Li G; Volquez M; Jering K; Cikes M; Kovacs A; Mullens W; Nicolau JC; Køber L; van der Meer P; Jhund PS; Ibram G; Lefkowitz M; Zhou Y; Solomon SD; Pfeffer MA
    Circulation; 2022 Oct; 146(14):1067-1081. PubMed ID: 36082663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal Changes in Natriuretic Peptides and Reverse Cardiac Remodeling in Patients with Heart Failure Treated with Sacubitril/Valsartan Across the Left Ventricular Ejection Traction Spectrum.
    Yamamoto M; Ishizu T; Sato K; Minami K; Terauchi T; Nakatsukasa T; Kawamatsu N; Machino-Ohtsuka T; Ieda M
    Int Heart J; 2023 Nov; 64(6):1071-1078. PubMed ID: 37967975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
    N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
    Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction.
    Chen F; Tian G; Bai X; Li J; Yuan Z
    Ann Palliat Med; 2021 Aug; 10(8):8684-8691. PubMed ID: 34488357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event.
    Mentz RJ; Ward JH; Hernandez AF; Lepage S; Morrow DA; Sarwat S; Sharma K; Solomon SD; Starling RC; Velazquez EJ; Williamson K; Zieroth S; Braunwald E
    J Card Fail; 2023 Jun; 29(6):922-930. PubMed ID: 36796671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.